U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H14NO.Br
Molecular Weight 220.1067
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FURTRETHONIUM BROMIDE

SMILES

C[N+](C)(C)Cc1ccco1.[Br-]

InChI

InChIKey=BXGSZEWYYLFSEJ-UHFFFAOYSA-M
InChI=1S/C8H14NO.BrH/c1-9(2,3)7-8-5-4-6-10-8;/h4-6H,7H2,1-3H3;1H/q+1;/p-1

HIDE SMILES / InChI

Molecular Formula C8H14NO
Molecular Weight 140.2032
Charge 1
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula BrH
Molecular Weight 80.9115
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

FURTRETHONIUM is an agonist of muscarinic acetylcholine receptors. It was used for the treatment of glaucoma.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Furmethide

Approved Use

Furtrethonum is a parasympathomimetic drug used for the treatment of glaucoma
Doses

Doses

DosePopulationAdverse events​
10 % 1 times / day multiple, ophthalmic
Dose: 10 %, 1 times / day
Route: ophthalmic
Route: multiple
Dose: 10 %, 1 times / day
Sources:
unhealthy
n = 21
Health Status: unhealthy
Condition: glaucoma
Population Size: 21
Sources:
Disc. AE: Dacryostenosis acquired...
AEs leading to
discontinuation/dose reduction:
Dacryostenosis acquired (71%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Dacryostenosis acquired 71%
Disc. AE
10 % 1 times / day multiple, ophthalmic
Dose: 10 %, 1 times / day
Route: ophthalmic
Route: multiple
Dose: 10 %, 1 times / day
Sources:
unhealthy
n = 21
Health Status: unhealthy
Condition: glaucoma
Population Size: 21
Sources:
PubMed

PubMed

TitleDatePubMed
Further studies on the use of furmethide in the treatment of glaucoma.
1946 Apr
The use of furmethide in comparison with pilocarpine and eserine for the treatment of glaucoma.
1947 Aug
Glaucoma treatment by furnethide and diisopropylfluorophosphate.
1949 Jul
Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors.
1997 Jul
Patents

Patents

Substance Class Chemical
Created
by admin
on Sat Jun 26 15:17:46 UTC 2021
Edited
by admin
on Sat Jun 26 15:17:46 UTC 2021
Record UNII
L22EQ82EJ0
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FURTRETHONIUM BROMIDE
Common Name English
FURFURYLTRIMETHYLAMMONIUM BROMIDE
Systematic Name English
2-FURANMETHANAMINIUM, N,N,N-TRIMETHYL-, BROMIDE
Systematic Name English
2-FURANMETHANAMINIUM, N,N,N-TRIMETHYL-, BROMIDE (1:1)
Systematic Name English
Code System Code Type Description
FDA UNII
L22EQ82EJ0
Created by admin on Sat Jun 26 15:17:46 UTC 2021 , Edited by admin on Sat Jun 26 15:17:46 UTC 2021
PRIMARY
PUBCHEM
52039
Created by admin on Sat Jun 26 15:17:46 UTC 2021 , Edited by admin on Sat Jun 26 15:17:46 UTC 2021
PRIMARY
CAS
73664-18-3
Created by admin on Sat Jun 26 15:17:46 UTC 2021 , Edited by admin on Sat Jun 26 15:17:46 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY